AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27548863 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 77
Study 27549244 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroTest for fibrosis staging
Number of subjects: 600
Study 27549244 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiTest for inflammation activity grading
Number of subjects: 600
Study 27549244 — intervention group
Group type: EXPERIMENTAL
Intervention: SteatoTest for steatosis grading
Number of subjects: 600
Study 27549584 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized low-sodium diet
Number of subjects: 25
Study 27549584 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum sodium intake (Control)
Number of subjects: 25
Study 27550351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam 3 g every 8 hours (q8h)
Number of subjects: 20
Study 27550526 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete en bloc omentectomy and modified D2 lymphadenectomy
Number of subjects: 100
Study 27551051 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine treatment
Number of subjects: 111
Study 27551171 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus 10 mg/day of native type II collagen (group AC+CII)
Number of subjects: 39
Study 27551171 — intervention group
Group type: COMPARATOR
Intervention: 1500 mg/day of acetaminophen (group AC)
Number of subjects: 39
Study 27551171 — intervention group
Group type: COMPARATOR
Intervention: Comparison between AC+CII and AC groups
Number of subjects: 39
Study 27551171 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 39
Study 27551314 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% caloric restriction (CR) diet for 3 weeks after a 2-week weight maintenance diet
Number of subjects: 19
Study 27551317 — intervention group
Group type: COMPARATOR
Intervention: Oxidized fish oil (8 g daily, EPA+DHA 1.6 g)
Number of subjects: 35
Study 27551317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality fish oil (8 g daily, EPA+DHA 1.6 g)
Number of subjects: 35
Study 27551569 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of an institutional registry of elderly patients with hip fracture
Number of subjects: 0
Study 27551569 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 and 12 months postfracture
Number of subjects: 0
Study 27551690 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-based lifestyle intervention for 12 months
Number of subjects: 223
Study 27551690 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start group (6-month delayed intervention)
Number of subjects: 223
Study 27551814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrashort echo-time MRI
Number of subjects: 11
Study 27551814 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 11
Study 27551991 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF minor allele
Number of subjects: 3180
Study 27551991 — intervention group
Group type: EXPERIMENTAL
Intervention: MC4R rs571312
Number of subjects: 3180
Study 27551991 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF rs2030323 (non-Hispanic white participants)
Number of subjects: 3180
Study 27551991 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO rs1421085 (non-Hispanic white participants)
Number of subjects: 3180
Study 27552578 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) treatment in Asia (1356 patients, 37.8%)
Number of subjects: 16162
Study 27552578 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) treatment in ORW (7081 patients, 53.3%)
Number of subjects: 16162
Study 27552827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal MRI techniques including structure magnetic resonance imaging (sMRI), resting state functional magnetic resonance imaging (rs-fMRI), diffusion kurtosis imaging (DKI), and three-dimensional pseudo-continuous arterial spin labeling (3D-pCASL)
Number of subjects: 159
Study 27552827 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 159
Study 27552827 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 159
Study 27552976 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (Tysabri®)
Number of subjects: 355
Study 27553184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation using plasma energy
Number of subjects: 104
Study 27553184 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy
Number of subjects: 104
Study 27553492 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised web-based physiotherapy programme
Number of subjects: 50
Study 27554014 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG IUS (levonorgestrel intrauterine system) 52 mg inserted at 2 weeks postpartum
Number of subjects: 50
Study 27554105 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary treatment (pharmacological and invasive)
Number of subjects: 0
Study 27555917 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming using XBOX Kinect™
Number of subjects: 50
Study 27555917 — intervention group
Group type: COMPARATOR
Intervention: Traditional gym-based exercise (TGB)
Number of subjects: 50
Study 27556153 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tube clearance (ATC)
Number of subjects: 252
Study 27556153 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest tube drainage
Number of subjects: 252
Study 27556234 — intervention group
Group type: EXPERIMENTAL
Intervention: SARP-3 cohort with exacerbation prone patients (≥3 exacerbations)
Number of subjects: 709
Study 27556389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear Acupuncture (EA)
Number of subjects: 80
Study 27556389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (detuned ultrasound)
Number of subjects: 80
Study 27556408 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exacerbations of COPD
Number of subjects: 2000
Study 27556408 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory events in smokers without COPD
Number of subjects: 2000
Study 27557531 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress measured by the 4-item Patient Health Questionnaire (PHQ-4)
Number of subjects: 1575
Study 27557531 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1575
Study 27557531 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid psychiatric disorder
Number of subjects: 1575
Study 27557531 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge to a post-acute care institution
Number of subjects: 1575
Study 27557531 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned rehospitalisation
Number of subjects: 1575
Study 27557531 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned visit at general practitioner
Number of subjects: 1575
Study 27557643 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor combined with pegylated liposomal doxorubicin (PLD)
Number of subjects: 0
Study 27557643 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor combined with doxorubicin
Number of subjects: 0
Study 27557643 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor/doxorubicin treatment
Number of subjects: 0
Study 27557643 — intervention group
Group type: COMPARATOR
Intervention: TOP2A knockdown
Number of subjects: 0
Study 27557655 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of total red meat consumption
Number of subjects: 74645
Study 27557657 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and fat loss intervention over 6 months
Number of subjects: 43
Study 27557657 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and fat loss intervention in iron-deficient subjects (n = 17)
Number of subjects: 43
Study 27557657 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and fat loss intervention in iron-sufficient subjects (n = 21)
Number of subjects: 43
Study 27557801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (VEND-RISK)
Number of subjects: 26
Study 27557949 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-related dopamine D2/3 receptor occupancy
Number of subjects: 41
Study 27557949 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 41
Study 27558140 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) exceeding 2 METs
Number of subjects: 410
Study 27558140 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) exceeding 3 METs
Number of subjects: 410
Study 27558140 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Time (ST)
Number of subjects: 410
Study 27558140 — intervention group
Group type: EXPERIMENTAL
Intervention: All PA categories (including Light PA, Moderate PA, Vigorous PA)
Number of subjects: 410
Study 27558140 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous Physical Activity (VPA)
Number of subjects: 410
Study 27558140 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Energy Expenditure (PAEE), Moderate PA (MPA), Vigorous PA (VPA)
Number of subjects: 410
Study 27558181 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin treatment
Number of subjects: 0
Study 27558181 — intervention group
Group type: EXPERIMENTAL
Intervention: C. difficile isolates characterization
Number of subjects: 0
Study 27558463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibiopedal access
Number of subjects: 197
Study 27558527 — intervention group
Group type: COMPARATOR
Intervention: Children with at least one piece of bedroom electronic media
Number of subjects: 5859
Study 27558527 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent physical activity in the home and yard
Number of subjects: 5859
Study 27558527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ownership of more frequently used play equipment
Number of subjects: 5859
Study 27558527 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher social support for physical activity
Number of subjects: 5859
Study 27558527 — intervention group
Group type: EXPERIMENTAL
Intervention: Play equipment ownership
Number of subjects: 5859
Study 27558635 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10^6 CEA-pulsed DCs mixed with tetanus toxoid (adjuvant) and low-dose interleukin-2 administered subcutaneously after final DC vaccination.
Number of subjects: 12
Study 27560141 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based childhood obesity treatment program
Number of subjects: 1125
Study 27561160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostar XL
Number of subjects: 585
Study 27561160 — intervention group
Group type: COMPARATOR
Intervention: ProGlide
Number of subjects: 585
Study 27561167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy in PEGASUS-like population (Group 1)
Number of subjects: 2490
Study 27561167 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2, patients with ≥1 exclusion criterion for the trial)
Number of subjects: 2490
Study 27561167 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3, patients meeting neither inclusion nor exclusion criteria)
Number of subjects: 2490
Study 27561167 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a risk factor in PEGASUS-like patients
Number of subjects: 2490
Study 27561198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon plus ribavirin therapy
Number of subjects: 156
Study 27561197 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class I
Number of subjects: 847
Study 27561197 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class II
Number of subjects: 847
Study 27561197 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class III
Number of subjects: 847
Study 27561197 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 847
Study 27561197 — intervention group
Group type: COMPARATOR
Intervention: Incidence of appropriate ICD intervention
Number of subjects: 847
Study 27561197 — intervention group
Group type: COMPARATOR
Intervention: Incidence of ICD-unresponsive sudden death
Number of subjects: 847
Study 27561272 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8150, single doses
Number of subjects: 0
Study 27561272 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8150, multiple doses
Number of subjects: 0
Study 27561272 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8150, 28-day studies
Number of subjects: 0
Study 27561272 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8150, preclinical studies in telemetered dogs
Number of subjects: 0
Study 27561720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (30 mg/m²) and cytosine arabinoside followed by reduced-intensity conditioning before allogeneic stem-cell transplantation
Number of subjects: 24
Study 27561722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ph-like ALL patients (n=19)
Number of subjects: 207
Study 27561722 — intervention group
Group type: COMPARATOR
Intervention: Remaining BCP-ALL patients (n=40)
Number of subjects: 207
Study 27561844 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBIRI (drug eluting PVA microspheres loaded with irinotecan)
Number of subjects: 40
Study 27561844 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBIRI (median dose of 103 mg irinotecan)
Number of subjects: 40
Study 27561844 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBIRI
Number of subjects: 40
Study 27562475 — intervention group
Group type: COMPARATOR
Intervention: Long-term CRC survivors
Number of subjects: 708
Study 27562938 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral endoscopic gastroplasty using a simple triangulation platform and a dedicated suturing device
Number of subjects: 11
Study 27564386 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bowel control system
Number of subjects: 110
Study 27565186 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors (smartwatch, smartphone, fall detector) used continuously for 3 months with a customized smartphone app (Fox Insight)
Number of subjects: 1000
Study 27565186 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors (smartwatch, smartphone, fall detector)
Number of subjects: 1000
Study 27565186 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported medication intake and fall incidents via smartphone app
Number of subjects: 1000
Study 27565186 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collected from wearable sensors
Number of subjects: 1000
Study 27565882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 8 weeks
Number of subjects: 2099
Study 27565882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 12 weeks
Number of subjects: 2099
Study 27565882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 24 weeks
Number of subjects: 2099
Study 27565882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 2099
Study 27565882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 24 weeks
Number of subjects: 2099
Study 27565932 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3026 at a dose of 125mg once daily
Number of subjects: 1
Study 27565932 — intervention group
Group type: EXPERIMENTAL
Intervention: LDK378 (ceritinib) at a dose of 750mg once daily
Number of subjects: 1
Study 27565932 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hyaluronan levels monitoring
Number of subjects: 1
Study 27566109 — intervention group
Group type: EXPERIMENTAL
Intervention: >20-43% IRS protection
Number of subjects: 289
Study 27566109 — intervention group
Group type: COMPARATOR
Intervention: >0-20% IRS protection
Number of subjects: 289
Study 27566109 — intervention group
Group type: COMPARATOR
Intervention: No IRS protection
Number of subjects: 289
Study 27566701 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022856 at doses of 5-30 mg/kg weekly (qwk)
Number of subjects: 44
Study 27566701 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022856 at 30 mg/kg qwk in colorectal cancer patients
Number of subjects: 44
Study 27566701 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022856
Number of subjects: 44
Study 27566720 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D longitudinal strain (2DLS) analysis
Number of subjects: 605
Study 27566720 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without ACS)
Number of subjects: 605
Study 27566836 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal stress
Number of subjects: 473
Study 27566836 — intervention group
Group type: COMPARATOR
Intervention: Pre- and perinatal stress
Number of subjects: 473
Study 27567280 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 27567500 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 20 mg/kg/day
Number of subjects: 180
Study 27567500 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 15 mg/kg/day
Number of subjects: 180
Study 27567500 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 10 mg/kg/day (control)
Number of subjects: 180
Study 27567680 — intervention group
Group type: EXPERIMENTAL
Intervention: Face transplantation
Number of subjects: 20
Study 27568125 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMP-DM
Number of subjects: 29870
Study 27568125 — intervention group
Group type: COMPARATOR
Intervention: Control (usual primary care)
Number of subjects: 29870
Study 27568453 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-dementia drugs (acetylcholinesterase inhibitors and memantine)
Number of subjects: 112
Study 27568453 — intervention group
Group type: COMPARATOR
Intervention: Control (patients with dementia who did not take anti-dementia drugs)
Number of subjects: 112
Study 27568864 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 4
Study 27570087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab consolidation (1000 mg once every 4 weeks)
Number of subjects: 34
Study 27570087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab induction (300 mg on day 1 and 1000 mg on day 2; cycles 2-6: 1000 mg on day 1)
Number of subjects: 34
Study 27570245 — intervention group
Group type: EXPERIMENTAL
Intervention: Delafloxacin 300 mg intravenous
Number of subjects: 3
Study 27570245 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 3
Study 27570627 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation (TELE group)
Number of subjects: 52
Study 27570627 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face rehabilitation (CLINIC group)
Number of subjects: 52
Study 27570807 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 c.-174 CC genotype
Number of subjects: 0
Study 27570807 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 genotypes
Number of subjects: 0
Study 27571185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 99
Study 27572392 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 2 g every 8 hours (q8h)
Number of subjects: 82
Study 27572392 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 8 hours (q8h)
Number of subjects: 82
Study 27572392 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 6 hours (q6h)
Number of subjects: 82
Study 27573206 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus followed by a 2-hour infusion)
Number of subjects: 67
Study 27573260 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 27573260 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 27573260 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 27573636 — intervention group
Group type: EXPERIMENTAL
Intervention: Group teleconferences after interim analyses
Number of subjects: 1741
Study 27573653 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab therapy (only group 1 showed significant benefit)
Number of subjects: 10468
Study 27573653 — intervention group
Group type: COMPARATOR
Intervention: Group 4 (not associated with significantly worse DFS or OS)
Number of subjects: 10468
Study 27573653 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (no significant benefit from trastuzumab therapy)
Number of subjects: 10468
Study 27573663 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine (6 mg/m2) administered once per week
Number of subjects: 0
Study 27573937 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 20
Study 27573937 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Adjustable Gastric Banding (LAGB)
Number of subjects: 20
Study 27573937 — intervention group
Group type: COMPARATOR
Intervention: Very Low Caloric Intake (VLCI)
Number of subjects: 20
Study 27574516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial weight-adjusted disability score (CombiWISE)
Number of subjects: 58
Study 27574516 — intervention group
Group type: EXPERIMENTAL
Intervention: CombiWISE
Number of subjects: 58
Study 27574837 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment (NCT00634803)
Number of subjects: 170
Study 27574837 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid treatment program-based methadone maintenance treatment (NCT00727675)
Number of subjects: 170
Study 27575787 — intervention group
Group type: EXPERIMENTAL
Intervention: Separable cluster electrode
Number of subjects: 79
Study 27575787 — intervention group
Group type: COMPARATOR
Intervention: Multiple internally-cooled electrodes
Number of subjects: 79
Study 27575911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Clearance Index (LCI)
Number of subjects: 97
Study 27575911 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 97
Study 27575911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Clearance Index (LCI) and Magnetic Resonance Imaging (MRI)
Number of subjects: 97
Study 27575984 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarit Burden Inventory (ZBI)
Number of subjects: 222
Study 27575984 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 222
Study 27575984 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living (IADL)
Number of subjects: 222
Study 27575984 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric Inventory (NPI)
Number of subjects: 222